NCT03631407View on ClinicalTrials.gov

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Colorectal Neoplasms
Interventions
DRUG

Vicriviroc

Vicriviroc tablets administered orally, QD at dose level 1 or 2.

BIOLOGICAL

Pembrolizumab

Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.

Trial Locations (8)

37203

Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000), Nashville

76508

Baylor Scott & White Medical Center - Temple ( Site 0104), Temple

85258

Honor Health ( Site 0103), Scottsdale

92024

California Cancer Associates for Research & Excellence ( Site 0100), Encinitas

93720

California Cancer Associates for Research & Excellence ( Site 0102), Fresno

33901-8101

Florida Cancer Specialists (South Region) - Research Office ( Site 7001), Fort Myers

T6G 1Z2

Cross Cancer Institute ( Site 0201), Edmonton

H1T 2M4

CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0204), Montreal

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | Biotech Hunter | Biotech Hunter